Good morning Bigkman I would like to know if you have any insight on this news PR concerning OSCIQ and Nanotherapeutics, Inc. and maybe any good out of this for OSCIQ, I wish they would have release a USD dollar amount on this transaction between to two companies.
News for 'OSCIQ' - (Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease)
OSCIQ News Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease.
Wednesday, December 16, 2009 9:02 AM
From:
"StockAlerts@scottrade.com" <StockAlerts@scottrade.com>
Scottrade.com
This email is compliments of Scottrade.com
News for 'OSCIQ' - (Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease)
ALACHUA, Fla., Dec 16, 2009 (BUSINESS WIRE) -- Nanotherapeutics, Inc., a
privately held biopharmaceutical company, announced that it has acquired in
bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient
Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc.
Ramoplanin - an oral antibiotic for the treatment of Clostridium
difficile-associated disease (CDAD) - is entering Phase 3 trials. PRX-3140 - an
orally-bioavailable Alzheimer's treatment - is in Phase 2 clinical studies.
Nanotherapeutics also acquired the U.S. and foreign patent estates covering each
clinical program.
About Ramoplanin and CDAD
CDAD ranges from uncomplicated diarrhea in its mildest form, to fulminant
colitis and death, in its most severe form. The incidence and severity of CDAD
has increased with the emergence of virulent strains creating a growing unmet
need. Ramoplanin, an orally administered drug, represents a potential new method
for managing certain pathogens commonly found in the hospital. Following oral
dosing Ramoplanin exerts its bactericidal activity locally in the GI tract and
is not absorbed systemically. Ramoplanin has been shown to be bactericidal in
vitro against C. difficile and other gram-positive bacteria and has been studied
through Phase 2 clinical trials. A Phase 3 non-inferiority trial against
vancomycin is planned pursuant to a Special Protocol Assessment agreed to by the
FDA.
CDAD was mainly a concern in older or severely ill patients who were hospital
inpatients or residents of long-term--care facilities. An increase of CDAD cases
has been reported in the U.S., Australia, Canada, and the United Kingdom.
Currently, it is estimated that 400,000 - 500,000 cases of CDAD occur each year
in the U.S., with the incidence apparently doubling from 1996 to 2003, including
a five-fold increase in those 65 and older. In the U.S., the disease generates
in excess of $2.8 billion annually in hospital health care costs.
About PRX-3140 and Alzheimer's Disease
PRX-3140 is intended to stimulate cognition and memory by selectively activating
the 5-HT4 G-protein coupled receptor in the brain to produce and release
acetylcholine, a neurotransmitter that plays a role in learning and memory. As
Alzheimer's disease progresses, acetylcholine production declines, and brain
levels of this critical neurotransmitter decline also. PRX-3140 may potentially
slow the progression of the disease with fewer and less severe side effects than
certain current Alzheimer drugs. A randomized, double-blind, placebo-controlled
Phase 2a clinical trial was completed to assess the effects of PRX-3140
following two weeks of treatment as monotherapy and separately in combination
with donepezil (Aricept(R)) in patients with mild Alzheimer's disease. In this
study, PRX-3140 appeared to be well tolerated alone and in combination with
Aricept(R) with no serious drug-related adverse events reported.
In October, 2009, the FDA permitted a Physician-Sponsored IND and continuation
of the fourth six-month open label extension of PRX-3140.
Alzheimer's disease is the most common form of dementia, affecting more than
five million Americans and over nine million worldwide. The National Institute
of Aging estimates that about five percent of the population aged 65-74 and as
many as 50% of the US population over 85 have the disease. The global market is
projected to grow from $4 billion in 2006 to over $5 billion in 2010. The
disease is currently incurable and manifests as progressive memory loss,
confusion, and ultimately loss of control of physical and mental functions
leading to death.
About Nanotherapeutics
Nanotherapeutics, Inc. is a privately held biopharmaceutical company. Its
product pipeline includes, an FDA-approved injectable biologic product
(Origen(TM) DBM, marketing partner Orthofix), an FDA filed product (NanoFUSE(TM)
bone graft), and other products in clinical trials including NanoDOX(R) and
NanoBUP(TM). The Company also has in-house GMP manufacturing to support
additional products. The 10-year old company employs several platform
technologies to manipulate and enhance the properties of drugs, has an
experienced management and development team, and a pipeline of clinical and
pre-clinical pharmaceutical and biologic products. For more information, visit
the Company website at www.nanotherapeutics.com.
SOURCE: Nanotherapeutics, Inc.
CONTACT:
Nanotherapeutics, Inc.
Weaver H. Gaines, 386-462-9663 Ext. 329
Chairman and General Counsel
wgaines@nanotherapeutics.com
Copyright Business Wire 2009
-0-
KEYWORD: United States
North America
Florida
INDUSTRY KEYWORD: Surgery
Technology
Nanotechnology
Health
Biotechnology
Clinical Trials
Hospitals
Pharmaceutical
Research
FDA
Science
SUBJECT CODE: Merger/Acquisition
Source: Comtext Market News
Market Data 
Markets 
AI
